Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity

Molecular and Cellular Biology

Volumn 24, Issue 19, 2004, Pages 8541-8555

  Ricci, M Stacey ^a   Jin, Zhaoyu ^a   Dews, Michael ^b   Yu, Duonan ^b   Thomas Tikhonenko, Andrei ^b   Dicker, David T ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 8; ESTROGEN RECEPTOR; FLICE INHIBITORY PROTEIN; LUCIFERASE; MYC PROTEIN; RECEPTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CULTURE; CHEMOSENSITIVITY; CHROMATIN; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; ENZYME DEGRADATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; SENSITIZATION; STIMULUS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4544253226     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.19.8541-8555.2004     Document Type: Article

References (71)

1. Amanullah, A., D. A. Liebermann, and B. Hoffman. 2002. Deregulated c-Myc prematurely recruits both type I and II CD95/Fas apoptotic pathways associated with terminal myeloid differentiation. Oncogene 21:1600-1610.
2. Ashkenazi, A. 2002. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2:420-430.
3. Ashkenazi, A., and V. M. Dixit. 1998. Death receptors: signaling and modulation. Science 281:1305-1308.
4. Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R. H. Schwall. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Investig. 104:155-162.
5. Aza-Blanc, P., C. L. Cooper, K. Wagner, S. Batalov, Q. L. Deveraux, and M. P. Cooke. 2003. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell 12:627-637.
6. Baran-Marszak, F., R. Fagard, B. Girard, S. Camilleri-Broet, F. Zeng, G. M. Lenoir, M. Raphael, and J. Feuillard. 2002. Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines. Lab. Investig. 82:1463-1479.
7. Blagosklonny, M. V., N. S. Prabhu, and W. S. El-Deiry. 1997. Defects in p21 WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res. 57:320-325.
8. Boyd, K. E., and P. J. Farnham. 1997. Myc versus USF: discrimination at the cad gene is determined by core promoter elements. Mol. Cell. Biol. 17:2529-2537.
9. Bullani, R. R., B. Huard, I. Viard-Leveugle, H. R. Byers, M. Irmler, J. H. Saurat, J. Tschopp, and L. E. French. 2001. Selective expression of FLIP in malignant melanocytic skin lesions. J. Investig. Dermatol. 117:360-364.
10. Burns, T., E. Bernhard, and W. El-Diery. 2001. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 20:4601-4612.
11. Burns, T. F., and W. S. El-Deiry. 2001. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276:37879-37886.
12. Butler, J. E., and J. T. Kadonaga. 2002. The RNA polymerase II core promoter: a key component in the regulation of gene expression. Genes Dev. 16:2583-2592.
13. Chang, D. W., Z. Xing, Y. Pan, A. Algeciras-Schimnich, B. C. Barnhart, S. Yaish-Ohad, M. E. Peter, and X. Yang. 2002. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 21:3704-3714.
14. Danielian, P. S., R. White, S. A. Hoare, S. E. Fawell, and M. G. Parker. 1993. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol. Endocrinol. 7:232-240.
15. Djerbi, M., V. Screpanti, A. I. Catrina, B. Bogen, P. Biberfeld, and A. Grandien. 1999. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190:1025-1032.
16. Eischen, C. M., G. Packham, J. Nip, B. E. Fee, S. W. Hiebert, G. P. Zambetti, and J. L. Cleveland. 2001. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 20:6983-6993.
17. Eischen, C. M., M. F. Roussel, S. J. Korsmeyer, and J. L. Cleveland. 2001. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 21:7653-7662.
18. Eischen, C. M., D. Woo, M. F. Roussel, and J. L. Cleveland. 2001. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol. Cell. Biol. 21:5063-5070.
19. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
20. El-Delry, W. S. 2001. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 8:1066-1075.
21. Evan, G. I., A. H. Wyllie, C. S. Gilbert, T. D. Littlewood, H. Land, M. Brooks, C. M. Waters, L. Z. Penn, and D. C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128.
22. Fernandez, P. C., S. R. Frank, L. Wang, M. Schroeder, S. Liu, J. Greene, A. Cocito, and B. Amati. 2003. Genomic targets of the human c-Myc protein. Genes Dev. 17:1115-1129.
23. Hadano, S., Y. Yanagisawa, J. Skaug, K. Fichter, J. Nasir, D. Martindale, B. F. Koop, S. W. Scherer, D. W. Nicholson, G. A. Rouleau, J. Ikeda, and M. R. Hayden. 2001. Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2. Genomics 71:200-213.
24. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95:2509-2514.
25. Hueber, A. O., M. Zornig, D. Lyon, T. Suda, S. Nagata, and G. I. Evan. 1997. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278:1305-1309.
26. Ichikawa, K., W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J. D. Mountz, W. J. Koopman, R. P. Kimberly, and T. Zhou. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7:954-960.
27. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J. L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. E. French, and J. Tschopp. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195.
28. Jin, Z., D. T. Dicker, and W. S. El-Deiry. 2002. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 1:82-89.
29. Jo, M., T. H. Kim, D. W. Seol, J. E. Esplen, K. Dorko, T. R. Billiar, and S. C. Strom. 2000. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6:564-567.
30. Juin, P., A. O. Hueber, T. Littlewood, and G. Evan. 1999. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13:1367-1381.
31. Juin, P., A. Hunt, T. Littlewood, B. Griffiths, L. B. Swigart, S. Korsmeyer, and G. Evan. 2002. c-Myc functionally cooperates with Bax to induce apoptosis. Mol. Cell. Biol. 22:6158-6169.
32. Kim, I. K., Y. K. Jung, D. Y. Noh, Y. S. Song, C. H. Choi, B. H. Oh, and E. S. Masuda. 2003. Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2. Br. J. Cancer 88:910-917.
33. Kim, K., M. J. Fisher, S.-Q. Xu, and W. S. El-Deiry. 2000. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6:335-346.
34. Klefstrom, J., I. Vastrik, E. Saksela, J. Valle, M. Eilers, and K. Alitalo. 1994. c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J. 13:5442-5450.
35. Krueger, A., S. Baumann, P. H. Krammer, and S. Kirchhoff. 2001. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 21:8247-8254.
36. Krueger, A., I. Schmitz, S. Baumann, P. H. Krammer, and S. Kirchhoff. 2001. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276:20633-20640.
37. Lawrence, D., Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, B. Mounho, K. Hillan, K. Totpal, L. DeForge, P. Schow, J. Hooley, S. Sherwood, R. Pai, S. Leung, L. Khan, B. Gliniak, J. Bussiere, C. A. Smith, S. S. Strom, S. Kelley, J. A. Fox, D. Thomas, and A. Ashkenazi. 2001. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7:383-385.
38. Littlewood, T. D., D. C. Hancock, P. S. Danielian, M. G. Parker, and G. I. Evan. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1686-1690.
39. Lutz, W., S. Fulda, I. Jeremias, K. M. Debatin, and M. Schwab. 1998. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 17:339-346.
40. MacLachlan, T. K., and W. S. El-Deiry. 2003. Identification of DNA-binding of tumor suppressor genes by chromatin immunoprecipitation. Methods Mol. Biol. 223:129-133.
41. Maclean, K. H., U. B. Keller, C. Rodriguez-Galindo, J. A. Nilsson, and J. L. Cleveland. 2003. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol. Cell. Biol. 23:7256-7270.
42. Magrath, I. 1990. The pathogenesis of Burkitt's lymphoma. Adv. Cancer Res. 55:133-270.
43. Medema, J. P., J. de Jong, T. van Hall, C. J. Melief, and R. Offringa. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190:1033-1038.
44. Menssen, A., and H. Hermeking. 2002. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc. Natl. Acad. Sci. USA 99:6274-6279.
45. Micheau, O., M. Thome, P. Schneider, N. Holler, J. Tschopp, D. W. Nicholson, C. Briand, and M. G. Grutter. 2002. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 277:45162-45171.
46. Mitchell, K. O., and W. S. El-Deiry. 1999. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 10:223-230.
47. Mitchell, K. O., M. S. Ricci, T. Miyashita, D. T. Dicker, Z. Jin, J. C. Reed, and W. S. El-Deiry. 2000. Bax is a transcriptional target and mediator of c-myc- induced apoptosis. Cancer Res. 60:6318-6325.
48. Mouzakiti, A., and G. Packham. 2003. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br. J. Haematol. 122:61-69.
49. Nesbit, C. E., J. M. Tersak, and E. V. Prochownik. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18:3004-3016.
50. Ngo, C. V., M. Gee, N. Akhtar, D. Yu, O. Volpert, R. Auerbach, and A. Thomas-Tikhonenko. 2000. An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ. 11:201-210.
51. Ozoren, N., M. J. Fisher, K. Kim, C. X. Liu, A. Genin, Y. Shifman, D. T. Dicker, N. B. Spinner, N. A. Lisitsyn, and W. S. El-Deiry. 2000. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol. 16:917-925.
52. Ozoren, N., K. Kim, T. F. Burns, D. T. Dicker, A. D. Moscioni, and W. S. El-Deiry. 2000. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 60:6259-6265.
53. Pear, W. S., J. P. Miller, L. Xu, J. C. Pui, B. Soffer, R. C. Quackenbush, A. M. Pendergast, R. Bronson, J. C. Aster, M. L. Scott, and D. Baltimore. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-3792.
54. Pelengaris, S., M. Khan, and G. Evan. 2002. c-myc: more than just a matter of life and death. Nat. Rev. Cancer 2:764-776.
55. Prabhu, N. S., M. V. Blagosklonny, Y:-U. Zeng, G. S. Wu, T. Waldman, and W. S. El-Deiry. 1996. Suppression of cancer cell growth by adenovirus expressing p21WAF1/CIP1 deficient in PCNA interaction. Clin. Cancer Res. 2:1221-1229.
56. Roth, W., S. Isenmann, U. Naumann, S. Kugler, M. Bahr, J. Dichgans, A. Ashkenazi, and M. Weller. 1999. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem. Biophys. Res. Commun. 265:479-483.
57. Ruf, I. K., P. W. Rhyne, H. Yang, C. M. Borza, L. M. Hutt-Fletcher, J. L. Cleveland, and J. T. Sample. 1999. Epstein-Barr virus regulates c-Myc, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol. Cell. Biol. 19:1651-1660.
58. Sevignani, C., P. Wlodarski, J. Kirillova, W. E. Mercer, K. G. Danielson, R. V. Iozzo, and B. Calabretta. 1998. Tumorigenic conversion of p53-deficient colon epithelial cells by an activated Ki-ras gene. J. Clin. Investig. 101:1572-1580.
59. Shivapurkar, N., J. Reddy, H. Matta, U. G. Sathyanarayana, C. X. Huang, S. Toyooka, J. D. Minna, P. M. Chaudhary, and A. F. Gazdar. 2002. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21: 8510-8514.
60. Soucie, E. L., M. G. Annis, J. Sedivy, J. Filmus, B. Leber, D. W. Andrews, and L. Z. Penn. 2001. Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol. Cell. Biol. 21:4725-4736.
61. Tepper, C. G., and M. F. Seldin. 1999. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 94:1727-1737.
62. Thomas, R. K., A. Kallenborn, C. Wickenhauser, J. L. Schultze, A. Draube, M. Vockerodt, D. Re, V. Diehl, and J. Wolf. 2002. Constitutive expression of c- FLIP in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 160:1521-1528.
63. Thome, M., P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattmann, K. Burns, J. L. Bodmer, M. Schroter, C. Scaffidi, P. H. Krammer, M. E. Peter, and J. Tschopp. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-521.
64. Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. Schuh, and D. H. Lynch. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157-163.
65. Wanzel, M., S. Herold, and M. Eilers. 2003. Transcriptional repression by Myc. Trends Cell Biol. 13:146-150.
66. Woods, D., D. Parry, H. Cherwinski, E. Bosch, E. Lees, and M. McMahon. 1997. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17:5598-5611.
67. Wu, G. S., and W. S. El-Deiry. 1996. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res. 2:623-633.
68. Xu, D., N. Popov, M. Hou, Q. Wang, M. Bjorkholm, A. Gruber, A. R. Menkel, and M. Henriksson. 2001. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA 98:3826-3831.
69. Yu, D., D. Allman, M. H. Goldschmidt, M. L. Atchison, J. G. Monroe, and A. Thomas-Tikhonenko. 2003. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 101:1950-1955.
70. Yu, D., and A. Thomas-Tikhonenko. 2002. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 21:1922-1927.
71. Zeller, K. I., A. G. Jegga, B. J. Aronow, K. A. O'Donnell, and C. V. Dang. 2003. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 4:R69.